Glaucoma is a chronic disease that can be challenging to treat for both patients and
physicians. Most patients will require more than 1 medication over time to maintain their …

Glaucoma is a complex, life-long disease that requires an individualized, multifaceted
approach to treatment. Most patients will be started on topical ocular hypotensive eyedrop …

Primary open-angle glaucoma (OAG) affects approximately 45 million people worldwide and
more than 2.5 million people aged 40 years or older in the United States. Pharmacologic …

Glaucoma causes irreversible vision loss, with elevated intraocular pressure (IOP) being the
only known modifiable risk factor. There are a variety of medical and interventional options …

Introduction Glaucoma is a progressive optic neuropathy and the leading cause of
irreversible vision loss. By 2040, the number of individuals with glaucoma is expected to …

The future of next generation therapeutics for glaucoma is strong. The recent approval of two
novel intraocular pressure (IOP)-lowering drugs with distinct mechanisms of action is the first …

Glaucoma refers to a collection of progressive optic neuropathies that can lead to
irreversible damage to retinal ganglion cells and their axons, and eventual loss of vision if …

Introduction Glaucoma is the leading cause of irreversible blindness worldwide. Medical
therapy is the main line of treatment of open-angle glaucoma (OAG) and ocular …

Introduction: In the last decades, the therapy of glaucoma has largely shifted from surgery to
medical treatment thanks to the introduction of strongly effective formulations, that is …

Although challenges in medical treatment of glaucoma exist, particularly in patient
adherence, medical therapy remains the first line treatment for almost all glaucoma patients …